Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors - Seite 3

Our SEC filings can be found on our website at www.zailaboratory.com and on the SEC’s website at www.sec.gov.

Reference:
1. Globocan 2020
2. Orgilmma Regzedmma etc. 2019, Oncotarget and Therapy
3. Statistics of Neuroendocrine Tumor in Cancer.Net [ASCO Knowledge Conquers Cancer]

View source version on businesswire.com: https://www.businesswire.com/news/home/20240313685689/en/

The Zai Lab Stock at the time of publication of the news with a raise of +3,28 % to 20,18EUR on Nasdaq stock exchange (13. März 2024, 23:16 Uhr).